leisure time -WSS

leisure time

author：focus 2025-09-04 04:43:12 - browse：77

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Investigation reveals sickle cell patients pressured into sterilizations

hotspot

WSS

Questions and answers about ramping up H5N1 bird flu vaccine

H5N1 virus can be tracked in retail milk, scientists say

For longer

Ambulance rides for just $100? Advisers want major billing fixes

HPV cancer vaccine study demonstrates efficacy

FDA approves Recor Medical high blood pressure device

focus

leisure time

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Biogen joins immunology wave with $1.15 billion acquisition of HI

Dobbs anniversary: the lost opportunity of abortion as health care

Cue Health, Covid

In Memoriam: Notable people who died in 2023

Eyeing GLP

Medical leaders decry Supreme Court decision on affirmative action

Questions and answers about ramping up H5N1 bird flu vaccine

DIEP, the 'gold standard' of breast reconstruction, is under threat

At flashy new research hub, AstraZeneca lays out ambitious growth goals

knowledge

Eyeing GLP

Making the case for fair compensation in clinical trials

STAT Executive Editor Rick Berke on STAT's 8th birthday

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Study: New antibiotic targets gonorrhea as well as last existing drug

hotspot

knowledge

hotspot

focus